COMPASS Pathways, a mental health treatment organization, obtained the designation for its psilocybin therapy for treatment-resistant depression in 2018. In 2019, Usona Institute, a nonprofit clinical researcher, acquired the designation to continue its testing of psilocybin for a treatment for main